Trial Profile
Effectiveness of Eplerenone to Improve Target Organ Damage in Patients With Resistant Arterial Hypertension.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Sep 2017
Price :
$35
*
At a glance
- Drugs Eplerenone (Primary)
- Indications Hypertension
- Focus Pharmacodynamics
- 17 Feb 2017 Results published in the Journal of Clinical Hypertension (Greenwich)
- 09 Feb 2010 Actual initiation date (Jan 2007) added as reported by ClinicalTrials.gov.
- 14 Aug 2009 Results were reported at the 19th European Meeting on Hypertension, held in Milan, Italy.